Overview of Leflon

Property	Description
Active ingredient	Leflunomide (a pro-drug)
Form	Film-coated tablet (oral)
Pharmacological class	Disease-Modifying Antirheumatic Drug (DMARD)
Common use	Systemic management of chronic autoimmune disorders
Origin	Synthetic compound (isoxazole derivative)

What Type of Medicine is Leflon (Leflunomide)?

Leflon is a prescription medication whose active ingredient, Leflunomide, is firmly established as a Disease-Modifying Antirheumatic Drug (DMARD) and an immunosuppressant. This classification is widely recognized in medical guidelines for the systemic management of chronic, inflammatory autoimmune disorders. Leflunomide is a synthetic compound, positioning it within the traditional DMARD class, distinct from the newer biologic agents. Its role is to help stabilize disease activity for patients with chronic conditions, a use supported by extensive clinical recognition.

Leflon's Composition, Form, and Unique Status

The medication is supplied as an oral formulation in the form of a film-coated tablet and contains Leflunomide as its single active ingredient. A key differentiating factor of Leflunomide is its status as a pro-drug, which requires metabolic conversion in the body into its active therapeutic agent, teriflunomide (or A77 1726). This mechanism of activation and its characteristic long half-life supports its general positioning as a long-acting DMARD suitable for long-term management.

General Role and Purpose of a DMARD

The general role of Leflon is to control the progression of chronic inflammation by selectively regulating the immune system. Its core mechanism involves inhibition of pyrimidine synthesis, a critical process necessary for the rapid growth of inflammatory immune cells, predominantly T-lymphocytes. This action provides targeted immunomodulation, aiming to minimize ongoing joint and tissue damage over time. The primary objective is to modify the underlying disease course, offering patients a method to sustain control over their condition.

What side effects are possible with Leflon?

Possible Side Effects and Safety Information

The safety profile of Leflon (Leflunomide) is structured by regulatory bodies based on the frequency and type of effects observed across different body systems. The classification of adverse reactions ranges from Very Common to Very Rare, as defined in official regulatory documents.

Classification of Officially Listed Adverse Reactions

The most frequently reported adverse reactions are related to the gastrointestinal system and hepatic function.

Very Common: These effects, which may affect more than 1 in 10 people, include diarrhea and elevated alanine aminotransferase (ALT), an indicator of potential liver effects.
Common: Affecting up to 1 in 10 people, these reactions include nausea, vomiting, oral ulceration, abdominal pain, an increase in blood pressure (hypertension), hair thinning (alopecia), rash, headache, and mild leucopenia.
Uncommon to Very Rare: Less frequent reactions include anemia, thrombocytopenia, hypokalemia, and the very rare potential for severe events like hepatic failure (sometimes fatal), severe infections (including sepsis), and pancytopenia.

Key Documented Safety Patterns and Restrictions

Official labeling highlights several key safety constraints. The greatest risk for hepatotoxicity (liver injury) and enzyme elevation is documented as occurring during the initial months of treatment. The medication is officially contraindicated for use in individuals with severe hepatic impairment and is also contraindicated during pregnancy due to a confirmed teratogenic risk. Furthermore, close monitoring of complete blood counts and liver enzyme levels is required for patients with pre-existing hematological or hepatic abnormalities.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is derived from official government regulatory documents detailing the potential manifestations and required emergency procedures for Leflunomide overdose.

Documented Clinical Manifestations

Overdose or excessive exposure to Leflon is officially associated with specific clinical manifestations. These may include gastrointestinal issues such as diarrhea and stomach pain, as well as systemic signs like extreme tiredness, weakness, pale skin, fast heartbeat, and shortness of breath. Laboratory findings may show changes in blood cell counts and alterations in liver function tests, which are crucial indicators monitored by physicians.

Requirement for Urgent Medical Attention

Immediate emergency assistance is required if an individual exhibits severe signs following exposure. These critical manifestations, detailed in official labeling, include collapse, seizure, trouble breathing, or inability to be awakened. In such scenarios, the regulatory guidance mandates immediately contacting emergency services and the poison control helpline.

Official Management and Monitoring

Management of toxicity or overdose focuses on an accelerated drug elimination procedure to rapidly reduce the plasma concentration of the active metabolite. This procedure often involves the use of agents such as Cholestyramine or activated charcoal. No specific antidote is documented for Leflunomide overdose; management relies entirely on elimination and supportive care. Following this intervention, official requirements mandate strict weekly monitoring of liver tests until normalization is achieved.

Therapeutic Uses of Leflon

What Leflon Treats: Main Uses and Benefits

Leflon (Leflunomide) is a Disease-Modifying Antirheumatic Drug (DMARD) primarily utilized for the long-term management of specific, chronic inflammatory autoimmune conditions in adults. The therapeutic approach is relevant to systemic control, used for long-term management of the disease. The medicine is indicated for the treatment of adults with active rheumatoid arthritis.

This medication is commonly used across conditions presenting with active systemic inflammation, specifically Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). It is generally applied in clinical settings marked by moderate to severe disease activity, where relevant for easing the overall systemic burden. The medication helps address symptom clusters that may become intense or disruptive, including chronic inflammatory joint pain and tenderness, persistent synovial swelling, and debilitating morning stiffness.

The key benefit is related to supporting long-term joint stability, and contributes to improved comfort during periods of heightened symptoms. Leflon is relevant when groups of symptoms create noticeable functional strain and interference with daily stability. It is relevant for easing symptomatic burden in conditions presenting with chronic inflammation.

“The therapy is relevant for easing symptomatic burden. It may assist with supporting functional stability and supporting a more manageable experience of physical function.”

Quick Fact: Relief for Inflammatory Joint Activity

It may assist with supporting functional stability and contribute to a more manageable experience of physical function over the long term, offering supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who can and cannot use Leflon?

Leflon (Leflunomide) is established for use only in adult patients with active rheumatoid arthritis or active psoriatic arthritis. Use is not recommended for patients below 18 years of age because safety and efficacy have not been established in this pediatric population. No specific dose adjustment is required for older adults above 65 years.

The medicine is absolutely contraindicated in several populations. These exclusions are primarily based on reproductive status and pre-existing health conditions. Leflon must not be used by pregnant women or breast-feeding women. Females of reproductive potential must use effective contraception during and for a specified period after treatment. Men intending to father a child should also consider a drug elimination procedure.

Contraindications based on health status include severe hepatic impairment, pre-existing acute or chronic liver disease, or baseline elevated liver enzymes (ALT >2x ULN). It is also prohibited for individuals with severe immunodeficiency states (such as AIDS), significantly impaired bone marrow function, severe hypoproteinaemia, or severe, uncontrolled infections. Use is not recommended in patients with moderate to severe renal insufficiency due to insufficient clinical data.

What should I know about interactions with other medicines?

Leflon's interaction profile is primarily defined by the activity of its active metabolite, teriflunomide, on metabolic pathways and drug transporters. The active metabolite is documented as a moderate inhibitor of CYP2C8 and an inhibitor of the OAT3, BCRP, and OATP1B1/B3 transporters, which may increase the plasma concentration of co-administered drugs that rely on these pathways for clearance. Conversely, it is also a weak inducer of CYP1A2, potentially reducing the exposure of substrates for that enzyme.

Co-administration of the pro-drug Leflon with Teriflunomide is formally contraindicated by regulatory bodies due to the risk of excessive active metabolite accumulation. Specific restrictions apply to certain interacting medicines; for instance, the co-administration of Rosuvastatin officially necessitates a dosage restriction, stating the dose must not exceed 10 mg once daily due to exposure risk.

Additive Toxicity and Procedural Requirements

The combination with other potentially hepatotoxic agents such as Methotrexate carries an officially documented risk of additive liver injury. Consumption of alcohol is similarly restricted due to the potential for increased hepatotoxicity. Use with other immunosuppressive or hematotoxic medicines increases the risk of additive myelosuppression.

A regulatory-mandated accelerated drug elimination procedure is documented for use when rapid clearance of the active metabolite is required. This procedure involves the administration of substances like Cholestyramine or Activated Charcoal to interrupt enterohepatic recirculation. The medicine is also contraindicated in patients with severe hepatic impairment.

Mechanism of Action

Targeting the Pyrimidine Synthesis Pathway

Leflon's primary action begins when its active metabolite, Teriflunomide, acts as a selective inhibitor of the mitochondrial enzyme Dihydroorotate Dehydrogenase (DHODH). This enzyme is crucial for the de novo pyrimidine synthesis pathway, leading to a functional deficiency of pyrimidine ribonucleotides (like UMP) required for building DNA and RNA. This fundamental metabolic interference is the basis of the molecule's pharmacodynamic action.

Cytostatic Control of Activated Immune Cells

The pyrimidine deficiency primarily affects activated T and B lymphocytes, which rely heavily on the DHODH-dependent pathway to sustain their rapid multiplication during an immune response. The mechanism forces these cells into a state of G1 cell cycle arrest, effectively limiting the clonal expansion of these self-reactive immune cell populations without causing cell death. This selective cytostatic effect results in a reduction of the overall population of activated immune cells.

Cascade to Systemic Immunomodulation

By reducing the population of activated immune cells, the drug initiates a cascade leading to systemic immunomodulation. The entire sequence modulates the ability of these cells to produce and release high concentrations of key pro-inflammatory mediators (e.g., TNF-alpha, IL-1). This biological action serves as the mechanistic foundation for long-term regulation of inflammatory signaling.

Dosage and Administration Information

How to Use Leflon: Administration Guidelines

Leflon (Leflunomide) is administered exclusively via the oral route as a film-coated tablet in strengths of 10 mg and 20 mg. The use of this medication must be initiated and supervised by specialists experienced in the treatment of chronic autoimmune conditions.

Dosing and Schedule

Leflunomide is typically administered once daily. Standard regimens provide for a choice between two starting methods:

Optional Loading Dose: Treatment may be initiated with a 100 mg once-daily dose taken for the first three days. This loading period may be omitted to potentially reduce the risk of adverse events in some patients.
Maintenance Dose: Following the loading period, or when starting without it, the standard long-term maintenance dose ranges from 10 mg to 20 mg once daily. The maximum recommended daily maintenance dose is 20 mg.

Tablets should be swallowed whole with sufficient liquid, and administration may occur with or without food. If a dose is missed, patients should continue with the next scheduled daily dose and not double the dose to compensate.

Course Duration and Special Procedures

As a Disease-Modifying Antirheumatic Drug (DMARD), Leflunomide is intended for long-term management. The therapeutic effect typically begins after four to six weeks, with further improvement potentially continuing for several months. For cases requiring the rapid removal of the drug from the bloodstream (e.g., prior to pregnancy), an accelerated elimination procedure is defined. This protocol involves the administration of substances like cholestyramine or activated charcoal over a designated duration, such as 11 days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Leflon (Leflunomide)

Evidence for Use in Active Rheumatoid Arthritis (RA)

Research into Leflon for adults with active Rheumatoid Arthritis (RA) includes multiple large Randomized Controlled Trials (RCTs). These studies were structured to explore how symptoms change over time by comparing outcomes in groups receiving Leflon against those receiving an inactive treatment (placebo) or other established arthritis medicines. Researchers monitored study populations to measure changes in outcomes related to systemic or functional imbalance, such as joint counts, and tracked changes in validated measures of daily functioning or activity level.

Studies conducted during periods of increased symptom activity reported that the frequency of patients achieving a measured clinical response (using standard criteria like the ACR response criteria) was reported to be higher compared to that observed in the placebo groups. Research also explored the effect on radiographic progression; studies monitored the rate of change in structural damage over observation periods of up to one year. Long-term studies extending beyond two years are typically unblinded observational studies, which are less controlled than the initial RCTs.

Evidence for Use in Active Psoriatic Arthritis (PsA)

Research related to Leflon for Active Psoriatic Arthritis (PsA) includes at least one large multinational, placebo-controlled clinical trial. This research examined specific populations of adults with active PsA, monitoring changes using specific criteria (PsARC) and measures of skin activity (PASI scores) over a period of 24 weeks. The core trial reported patterns where the frequency of patients meeting the PsARC responder criteria at 24 weeks was observed to be higher in the active group compared to the placebo group. Comparative evidence exploring outcomes against all currently available treatment classes, particularly newer biologics, remains limited in the published RCT base.

Duration of Study and Long-Term Follow-up

The typical follow-up durations in the primary randomized clinical trials were generally short-term (6 months) to intermediate-term (up to 2 years). The data show patterns related to the consistency of the initially measured outcomes in these defined time intervals. When considering extended use beyond two years, the information available generally comes from observational registry data, which are relevant to exploring sustained use.

Gaps in Research and Areas of Uncertainty

The scientific literature highlights that the long-term effects are not fully established under strictly controlled, blinded conditions extending past two years. Data show patterns related to drug persistence in the observational cohorts, but the evidence quality varies across studies, meaning findings describe group patterns, not personal outcomes. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Leflon (FAQ)

Q: How quickly does Leflon usually start to work?

The initial therapeutic effect of Leflon is typically observed after approximately four to six weeks of treatment. According to official product information, the active substance is estimated to require nearly two months of continuous dosing to reach a steady concentration in the body if a loading dose is not utilized.

Q: Is Leflon a long-term treatment or a short-term one?

Official documents describe Leflon as a medication intended for the long-term management of chronic autoimmune conditions. Because the active substance remains in the body for an extended period, an accelerated elimination procedure is described as an option when discontinuation is considered for certain health reasons.

Q: Can Leflon affect sleep or cause drowsiness?

Regulatory documents list headache and dizziness as common side effects, affecting up to 1 in 10 people. While the specific terms 'drowsiness' or 'sleep disturbance' are not commonly listed, official documents describe dizziness as an officially described adverse reaction.

Q: What are the most common non-serious side effects of Leflon?

The most frequent documented side effect, affecting more than 1 in 10 people, is diarrhea. Other common effects, observed in up to 1 in 10 people, include gastrointestinal symptoms like nausea, vomiting, and abdominal pain, as well as rash, headache, and hair thinning (alopecia).

Q: What happens if a dose of Leflon is missed?

The active substance of Leflon has a very long half-life, meaning it stays in the body for an extended time. Official guidelines describe the recommendation to continue with the next scheduled daily dose.

Q: How long after stopping Leflon does it stay in your system?

Due to the long half-life of the active substance, it is estimated that it may take up to two years to reach a non-detectable level in the bloodstream naturally. Regulatory documents outline an accelerated drug elimination procedure that can be used to clear the active substance from the body much faster.

Q: What percentage of patients experience the common side effects listed for Leflon?

Official safety data classifies side effects based on how often they occurred in clinical trials. Very Common effects are those observed in more than 10% (more than 1 in 10) of people. Common effects are observed in up to 10% (up to 1 in 10) of people.

Q: Can taking Leflon cause stomach upset or nausea?

Yes, regulatory documents list gastrointestinal issues as common side effects. Specifically, nausea, vomiting, and abdominal pain are documented in up to 1 in 10 people in clinical trials, which encompasses what patients often describe as stomach upset.

Q: Is Leflon known to interact with caffeine?

The active substance in Leflon is described as a weak inducer of CYP1A2, an enzyme that plays a role in processing substances. Official documents describe caffeine as a substance that may interact with Leflon.

Q: Do you need to stop taking Leflon suddenly, or should it be gradual?

For specific safety considerations, such as a female patient intending to become pregnant or suspected liver injury, official guidelines describe the recommendation for an accelerated drug elimination procedure upon discontinuation. This procedure involves taking specific medications over several days to remove the active substance from the body.

Q: Can Leflon cause changes in appetite?

Loss of appetite is documented in official sources as a possible symptom associated with the risk of liver injury, which is a key safety pattern for the drug.

Q: Is it normal to feel tired during the first few days of taking Leflon?

Unusual tiredness or weakness is documented in regulatory safety information as a symptom that may be associated with potential, serious issues, such as low blood cell count or liver effects. These types of symptoms are typically highlighted in safety information.

Q: Does Leflon cause weight gain or weight loss?

Unexplained weight loss is listed in some official safety information and is also documented as a possible symptom of liver toxicity. Weight gain is not listed as a commonly documented side effect associated with the use of this medicine.

Q: Can I take multivitamins or supplements while on Leflon?

Regulatory sources highlight the risk of interactions with specific substances, such as Vitamin D analogs, due to the potential for impacting calcium and phosphate levels. There are no general statements covering all multivitamins or supplements; patients typically seek information regarding the safety of specific supplements due to the absence of a general statement.

Q: Are there any specific lifestyle changes recommended while taking Leflon?

Regulatory guidance strictly restricts the consumption of alcohol due to the potential for increased liver toxicity. Additionally, official documents describe precautions that may be necessary, such as avoiding contact sports if blood cell counts become low.

Q: Is there a generic version of Leflon available?

Yes, the FDA has approved generic versions of the active ingredient, leflunomide. These generic products are approved by the FDA based on having the same active ingredient, dose, and similar therapeutic effects as the original brand product.

Q: Can people with diabetes use Leflon?

Diabetes is not listed as an absolute contraindication for use. However, official documents state that having pre-existing diabetes is a factor that may increase the risk of experiencing peripheral neuropathy (nerve damage) while taking this medicine.

Q: Does Leflon have a warning about driving or operating machinery?

Official labeling lists dizziness as a common side effect. Although a specific, direct warning about driving or operating heavy machinery may not be consistently stated, official documents describe dizziness as an adverse reaction.

How should Leflon be stored and disposed of?

How to Store and Dispose of Leflunomide

Leflunomide (Leflon) must be stored and disposed of according to official regulatory requirements to ensure product integrity and environmental safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at 20 C to 25 C (68 F to 77 F). Do not store above 25 C.
Protection	Keep away from excess heat and moisture, and protect from light.
Container	Store in the original container, which must be kept tightly closed.
Child Safety	Keep this medicine strictly out of the sight and reach of children.

Leflunomide should not be used past the expiry date printed on the packaging.

Disposal Instructions

Official disposal rules mandate that unused or expired Leflunomide must not be thrown away via wastewater or general household waste. For proper environmental disposal, patients are required to ask a pharmacist how to safely throw away the medicine you no longer need. In jurisdictions where take-back programs are not available, specific guidelines recommend mixing the product with an undesirable substance before discarding in the trash.

Leflon